

27 January 2022

## Attention:

Ms Michaels

The Society of Hospital Pharmacists of Australia (SHPA)

## RE. NOTIFICATION OF OUT OF STOCK PERIOD FOR YERYOY (IPILIMUMAB) 200MG/40ML AND 50MG/10ML VIALS CONCENTRATE SOLUTION FOR INTRAVENOUS INFUSION

Dear Ms Michaels.

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to provide a further update from our correspondence on 11 January regarding the Yervoy (Ipilimumab) out of stock period:

- The out of stock period for Yervoy (Ipilimumab) 200mg /40mL vial concentrate solution for intravenous infusion is no longer anticipated, it is current as of 14 January. The out of stock period has been revised from 3-4 weeks and is now anticipated to last 8 weeks.
- From the 1 February 2022 we anticipate Yervoy (Ipilimumab) 50mg /10mL vial concentrate solution for intravenous infusion will also be out of stock in Australia and not available. We anticipate that this situation will last 2 weeks.

These stock shortages are related to demand surges, shipment delays and availability of raw materials. We are working to resolve this matter as soon as possible. BMS knows the importance of a steady and reliable supply of critical medicines for patients and remains committed to delivering this medicine to patients who need it.

BMS have notified the Therapeutics Goods Administration (TGA) of this supply shortage.

If you could please disseminate this information to the SHPA members, it would be greatly appreciated.

## **Product Details**

BMS Code	BMS Product	Out of Stock Status	Resolved
1279684	YERVOY SINJ 200MG (1VLX40ML) AU/NZ	Current as of 14 January 2022 January 2022	Revised from late February to Mid- March 2022
1279683	YERVOY SINJ 50MG (1VLX10ML) AU/NZ	Anticipated week commencing 1 February 2022	Mid-February 2022

If you have any questions relating to the shortage, please contact the BMS Medical Information Department at 1800 067 567 or via email at: medinfo.australia@bms.com.

Yours sincerely,

Kate Church Bristol-Myers Squibb Australia